LMN-201
PreclinicalSmall molecule
LMN-201 is one of 8 small molecule programs targeting Clostridioides difficile Infection. It is currently in Preclinical.
1
Indications
2
Total Trials
1
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
9 competitors in Clostridioides Difficile Infection
#DrugCompanyPhaseTrials
1Vancomycin or Fidaxomicin
SSejtterapia Kozpont Kft.
Phase 3
EXL01
EExeliom Biosciences
Phase 2
Dificlir
Merck & Co.Preclinical
AZD5148
AstraZenecaPhase 2
ZINPLAVA
Merck & Co.Preclinical
CMTS0929
TThe Second Hospital of Nanjing Medical University
Phase 1
Vancomycin (VAN) Treatment
UUniversity Hospital, Montpellier
Preclinical
LMN-201
LLumen Bioscience, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for LMN-201. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- LLumen Bioscience, Inc.